Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corindus Vascular Robotics, Inc.CVRS · Entity 154132 | Director | December 15, 2017 | March 07, 2018 |
| Neuronetics, Inc.STIM · Entity 6248 | Director | May 24, 2023 | May 26, 2023 |
| TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943 | Director | May 19, 2026 | May 20, 2026 |
| Xtant Medical Holdings, Inc.XTNT · Entity 7196 | Director | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corindus Vascular Robotics, Inc.
Report date December 15, 2017 · Filed March 07, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,072 |
Reported balance
After 2017-12-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-12-15 · Grant · Acquired 32,072 · Balance 32,072 F1: The common stock represents shares issuable upon vesting of restricted stock units granted as part of the director's annual equity award. The RSUs were initially vested with respect to one quarter of the granted units. The remaining quarterly installments will vest on February 8, 2018, May 8, 2018 and August 8, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The common stock represents shares issuable upon vesting of restricted stock units granted as part of the director's annual equity award. The RSUs were initially vested with respect to one quarter of the granted units. The remaining quarterly installments will vest on February 8, 2018, May 8, 2018 and August 8, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date.
Neuronetics, Inc.
Report date May 24, 2023 · Filed May 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,352 |
Ending reported balance
After 2023-05-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-05-24 · Sale · Disposed 14,400 · Balance 77,988 F1: The sales reported in this Form 4 were pursuant to a 10b5-1 plan validly adopted by the reporting person to cover the reporting person's tax liability from a restricted stock unit ("RSU") award vesting on May 26, 2023. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $2.60 to $2.77. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2023-05-25 · Grant · Acquired 36,364 · Balance 114,352 F3: Represents an RSU award that vests on the earlier of (a) May 23, 2024, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date. F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were pursuant to a 10b5-1 plan validly adopted by the reporting person to cover the reporting person's tax liability from a restricted stock unit ("RSU") award vesting on May 26, 2023.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $2.60 to $2.77. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Represents an RSU award that vests on the earlier of (a) May 23, 2024, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
TREACE MEDICAL CONCEPTS, INC.
Report date May 19, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 204,056 |
Reported balance
After 2026-05-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 30,000 · Balance 204,056 F1: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date. F2: Includes 30,000 restricted stock units. |
| Common SotckSEC Table I · non-derivative | IndirectBy spouse as trustee of a trust | 250,000 |
Reported balance
Holding disclosure · report date 2026-05-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 250,000 |
| Common StockSEC Table I · non-derivative | IndirectAs trustee of a trust | 92,300 |
Reported balance
Holding disclosure · report date 2026-05-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 92,300 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date.
F2: Includes 30,000 restricted stock units.
Xtant Medical Holdings, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,129,633 |
Reported balance
After 2026-08-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 215,517 · Balance 1,129,633 F1: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock. F2: Includes 681,087 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.
F2: Includes 681,087 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ENTELLUS MEDICAL INC
Report date February 28, 2018 · Filed March 01, 2018
Section 16 reporting ended · disclosed 2018-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 1
1 source rowRow 1 · 2018-02-28 · Disposition to issuer · Disposed 2,500 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-28 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.38 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-28 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share.
F2: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
F3: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2026 Filed Aug 18, 2026 22:27 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock | 215,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001183553-26-000001 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,129,633 F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 681,087 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date. Read SEC document |
| May 19, 2026 Filed May 20, 2026 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-231466 · ownership.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,056 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date. F2 · balance_after: Includes 30,000 restricted stock units. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 22:53 UTC Amendment | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock | 158,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001183553-25-000006 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914,116 F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 465,570 shares issuable upon settlement of DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates. F3 · balance_after: The purpose of this Form 4 amendment is to correct the number of shares beneficially held in column 5. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 22:15 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock | 158,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001183553-25-000005 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,228 F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 465,570 shares issuable upon settlement of DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates. Read SEC document |
| May 20, 2025 Filed May 21, 2025 21:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 23,917 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-075888 · ownership.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,056 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 20, 2026 or (b) the date of the 2026 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date. F2 · balance_after: Includes 23,917 restricted stock units. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:32 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock | 162,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-24-000067 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 755,888 F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2025, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. F2 · balance_after: Includes 307,342 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 33,260 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0000950170-24-063617 · ownership.xml · derivative · entry 4 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,260 Underlying: Common Stock · 33,260 shares Expires 2034-05-21 F3 · derivative.exercise_date: The stock option will vest in 12 substantially equal monthly installments, commencing on June 21, 2024, such that the stock option will be fully vested and exercisable on the earlier of (a) May 21, 2025, or (b) the date of the 2025 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 15,091 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-063617 · ownership.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,139 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 21, 2025 or (b) the date of the 2025 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date. F2 · balance_after: Includes 15,091 restricted stock units. Read SEC document |
| May 10, 2024 Filed May 13, 2024 23:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 130,000 | $4.57 | $594,620.00 |
DisclosureSEC source: 0000950170-24-058974 · ownership.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,048 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.425 to $4.6186, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 2,753 restricted stock units. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:10 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantStock Option (right to buy) · Derivative | 28,230 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001235802-23-000090 · primary_doc.xml · derivative · entry 2 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,230 Underlying: Common Stock · 28,230 shares Expires 2033-08-15 F3 · derivative.exercise_date: This option vests on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:10 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock | 145,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-23-000090 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 593,726 F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. F2 · balance_after: Includes 145,180 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:10 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 36,364 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-012301 · form4.xml · nonDerivative · entry 2 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,352 F3 · shares: Represents an RSU award that vests on the earlier of (a) May 23, 2024, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date. F4 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:10 UTC | Neuronetics, Inc. STIM · Entity 6248 | SaleCommon Stock | 14,400 | $2.70 | $38,880.00 |
DisclosureSEC source: 0001062993-23-012301 · form4.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,988 F1 · shares: The sales reported in this Form 4 were pursuant to a 10b5-1 plan validly adopted by the reporting person to cover the reporting person's tax liability from a restricted stock unit ("RSU") award vesting on May 26, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $2.60 to $2.77. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2023 Filed May 26, 2023 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 6,305 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0001209191-23-032354 · doc4.xml · derivative · entry 4 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,305 Underlying: Common Stock · 6,305 shares Expires 2033-05-23 F3 · derivative.exercise_date: The stock option will vest in 12 substantially equal monthly installments, commencing on June 23, 2023, such that the stock option will be fully vested and exercisable on the earlier of (a) May 23, 2024, or (b) the date of the 2024 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| May 23, 2023 Filed May 26, 2023 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 2,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032354 · doc4.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,048 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 23, 2024 or (b) the date of the 2024 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date. F2 · balance_after: Includes 2,753 RSUs. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:37 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock, $0.000001 par value | 215,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-22-000097 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,546 F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. F2 · balance_after: Includes 215,415 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:29 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 38,910 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-013871 · form4.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,388 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 26, 2023, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: Reflects an adjustment to total holdings to include 4,050 shares that were reported on a Form 3/A filed on August 20, 2020 but inadvertently omitted from subsequent reports. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:33 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 16,625 | $0.00 Strike: $15.80 | $0.00 |
DisclosureSEC source: 0001567619-22-011340 · doc1.xml · derivative · entry 4 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,625 Underlying: Common Stock · 16,625 shares Expires 2032-05-17 F2 · derivative.exercise_date: The stock option will vest in 12 substantially equal monthly installments, commencing on June 17, 2022, such that the stock option will be fully vested and exercisable on May 17, 2023, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:33 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 2,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011340 · doc1.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,295 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on May 17, 2023 subject to Reporting Person's providing continued service to Issuer through the vesting date. Read SEC document |
| October 06, 2021 Filed Feb 11, 2022 21:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 92,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003544 · doc1.xml · nonDerivative · entry 8 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John K. Bakewell, as Trustee of family trust #2 Disclosed balance after: 92,300 Read SEC document |
| October 06, 2021 Filed Feb 11, 2022 21:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 92,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003544 · doc1.xml · nonDerivative · entry 7 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deborah M. Bakewell Disclosed balance after: 0 F1 · ownership.nature: The shares are directly held by the Reporting Person's wife. Read SEC document |
| October 06, 2021 Filed Feb 11, 2022 21:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003544 · doc1.xml · nonDerivative · entry 6 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deborah M. Bakewell, as Trustee of family trust #1 Disclosed balance after: 250,000 Read SEC document |
| October 06, 2021 Filed Feb 11, 2022 21:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003544 · doc1.xml · nonDerivative · entry 5 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 15, 2021 Filed Aug 17, 2021 21:19 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock, $0.000001 par value | 85,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-21-000107 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,131 F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date. F2 · balance_after: Includes 143,436 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date. Read SEC document |
| August 11, 2021 Filed Feb 11, 2022 21:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 92,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003544 · doc1.xml · nonDerivative · entry 4 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deborah M. Bakewell Disclosed balance after: 92,300 F1 · ownership.nature: The shares are directly held by the Reporting Person's wife. Read SEC document |
| August 11, 2021 Filed Feb 11, 2022 21:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 92,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003544 · doc1.xml · nonDerivative · entry 3 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John K. Bakewell and Deborah M. Bakewell, Co-Owners with Rights of Survivorship Disclosed balance after: 0 Read SEC document |
| August 11, 2021 Filed Feb 11, 2022 21:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003544 · doc1.xml · nonDerivative · entry 2 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Read SEC document |
| August 11, 2021 Filed Feb 11, 2022 21:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003544 · doc1.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John K. Bakewell and Deborah M. Bakewell, Co-Owners with Rights of Survivorship Disclosed balance after: 92,300 Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 22:28 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 7,137 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-005247 · form4.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,428 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 27, 2022, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 27, 2021 Filed Apr 30, 2021 01:10 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionSeries A Preferred Stock · Derivative | 342,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017465 · doc4.xml · derivative · entry 3 BAKEWELL JOHN K · CIK 0001183553 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Indirect · John K. Bakewell and Deborah M. Bakewell, Co-Owners with Rights of Survivorship Disclosed balance after: 0 Underlying: Common Stock · 342,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 30, 2021 01:10 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | OtherSeries A Preferred Stock · Derivative | 7,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017465 · doc4.xml · derivative · entry 2 BAKEWELL JOHN K · CIK 0001183553 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Indirect · John K. Bakewell and Deborah M. Bakewell, Co-Owners with Rights of Survivorship Disclosed balance after: 342,300 Underlying: Common Stock · 7,925 shares Expires not disclosed F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_price: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.expiration_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. Read SEC document |
| April 27, 2021 Filed Apr 30, 2021 01:10 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionCommon Stock | 342,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-017465 · doc4.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Indirect · John K. Bakewell and Deborah M. Bakewell, Co-Owners with Rights of Survivorship Disclosed balance after: 342,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| April 22, 2021 Filed Apr 27, 2021 00:55 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option Right to Buy · Derivative | 21,240 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017024 · doc4.xml · derivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,240 Underlying: Common Stock · 21,240 shares Expires 2031-04-22 F1 · derivative.exercise_date: The stock option will vest in 12 substantially equal installments, commencing on May 22, 2021, such that the stock option will be fully vested and exercisable on April 22, 2022, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:14 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 12,291 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-20-000648 · edgar.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,291 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) August 5, 2021, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:15 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-20-000401 · edgar.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 26, 2021, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:12 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock, $0.000001 par value | 116,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-20-000003 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,794 F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 58,098 shares on February 15, 2021 and with respect to 58,099 shares on February 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date. F2 · balance_after: Includes (i) 116,197 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date; (ii) 5,555 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and (iii) 13,021 shares issued as part of a restricted stock award granted under the Amended and Restated Xtant Equity Incentive Plan, which shares are subject to forfeiture until vested. Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 20:36 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock, $0.000001 par value | 5,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-19-000122 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,597 F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon the reporting person remaining a director of Xtant through the vesting date. F2 · balance_after: Includes 5,555 shares to be issued upon vesting pursuant to restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and 13,021 shares issued as part of a restricted stock award granted under the Amended and Restated Xtant Equity Incentive Plan, which shares are subject to forfeiture until vested. Read SEC document |
| April 09, 2018 Filed Apr 10, 2018 23:00 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock | 26,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-020004 · tv490829_4.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,042 F1 · shares: The common stock vests as follows: (i) 13,021 shares of common stock vests on February 15, 2019, and (ii) 13,021 shares of common stock vests of February 15, 2020. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 15:34 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $10.62 Strike: $13.38 | $53,100.00 |
DisclosureSEC source: 0001235802-18-000029 · primary_doc.xml · derivative · entry 3 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-06-13 F3 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 15:34 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $5.74 Strike: $18.26 | $57,400.00 |
DisclosureSEC source: 0001235802-18-000029 · primary_doc.xml · derivative · entry 2 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-14 F2 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 15:34 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerCommon Stock, $0.001 par value | 2,500 | $24.00 | $60,000.00 |
DisclosureSEC source: 0001235802-18-000029 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:36 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantRestricted Stock Units · Derivative | 32,072 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-17-005914 · bakewell-form4_121517.xml · derivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,072 Underlying: Common Stock · 32,072 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock, par value $0.0001 per share, of Corindus Vascular Robotics, Inc. F2 · derivative.exercise_date: The restricted stock units were granted on December 15, 2017 as part of the director's annual equity award with vesting beginning as of August 8, 2017, the date of the reporting person's appointment as a director. The restricted stock units vest in four equal quarterly installments on November 8, 2017, February 8, 2018, May 8, 2018 and August 8, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Vested shares will be delivered to the reporting person within five days of each such vesting date. F2 · derivative.expiration_date: The restricted stock units were granted on December 15, 2017 as part of the director's annual equity award with vesting beginning as of August 8, 2017, the date of the reporting person's appointment as a director. The restricted stock units vest in four equal quarterly installments on November 8, 2017, February 8, 2018, May 8, 2018 and August 8, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Vested shares will be delivered to the reporting person within five days of each such vesting date. Read SEC document |
| December 15, 2017 Filed Mar 7, 2018 00:00 UTC Amendment | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 32,072 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-18-000939 · bakewell-form4a_121517.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,072 F1 · balance_after: The common stock represents shares issuable upon vesting of restricted stock units granted as part of the director's annual equity award. The RSUs were initially vested with respect to one quarter of the granted units. The remaining quarterly installments will vest on February 8, 2018, May 8, 2018 and August 8, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 16:04 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0001235802-17-000079 · primary_doc.xml · derivative · entry 2 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-13 F2 · derivative.exercise_date: This option vests in full on the earlier to occur of June 13, 2018 and the date of the Company's annual meeting of stockholders immediately following June 13, 2017, subject to the Reporting Person's continued service with the Company through the applicable vesting date. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 16:04 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | GrantCommon Stock, $0.001 par value | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-17-000079 · primary_doc.xml · nonDerivative · entry 1 BAKEWELL JOHN K · CIK 0001183553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · shares: These shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan. F1 · balance_after: These shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.